Laboratory and clinical studies on T-3262

Mitsuo Kaku, Yuichii Noue, Kyoko Yamashitah, Ideo Mashimoto, Miyako Ishiguro, Yasuharu Masuyama, Yasumasa Dotsu, Takashi Suyama, Toshiaki Hayashi, Shigeru Kohno, Keizo Yamaguchi, Masaki Hirota, Kohei Hara, Toyohiro Sasaki, Chikako Mochida, Kazuyuki Sugahara, Toshiaki Usui, Koichi Watanabe, Tsuneo Tsutsumi, Toshiro OdaHirosuke Ohta, Isao Nakamura, Teruhiko Rikitake, Hirokom Otonaga, Takashi Ishizaki

Research output: Contribution to journalArticlepeer-review


We carried out laboratory and clinical studies on T-3262, a new antimicrobial agent, and obtained the following results. 1) Antimicrobial activity: the in vitro antimicrobial activity of T-3262 was determined against 30 standard strains and 543 clinical isolates of 16 different species by a microbroth dilution method using the Dynateck system MIC 2000 and compared with those of pipemidic acid (PPA), norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX). Results: T-3262 showed excellent activity against both Gram-positive cocci and Gram-negative bacilli of standard strains and clinical isolates. 2) Clinical efficacy and adverse reactions: 17 patients with respiratory infection (pneumonia 6, chronic bronchitis 7, diffuse panbronchiolitis 3, acute bronchitis 1) and 3 patients with dysentery were treated with T-3262. The overall efficacy rate was 84. 2%(excellent 3, good 13, fair 3, not evaluable 1). No side effect or abnormal laboratory finding was observed. We therefore conclude that T-3262 is a useful antibiotic in treating patients with respiratory and intestinal infections.

Original languageEnglish
Pages (from-to)661-674
Number of pages14
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on T-3262'. Together they form a unique fingerprint.

Cite this